WO2005084712A3 - Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment - Google Patents

Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment Download PDF

Info

Publication number
WO2005084712A3
WO2005084712A3 PCT/EP2005/002101 EP2005002101W WO2005084712A3 WO 2005084712 A3 WO2005084712 A3 WO 2005084712A3 EP 2005002101 W EP2005002101 W EP 2005002101W WO 2005084712 A3 WO2005084712 A3 WO 2005084712A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
metastases
formation
preparation
inhibiting
Prior art date
Application number
PCT/EP2005/002101
Other languages
French (fr)
Other versions
WO2005084712A2 (en
Inventor
Karl-Hermann Schlingensiepen
Reimar Schlingensiepen
Piotr Jachimczak
Gerhard Stauder
Astrid Bischof
Michael Hafner
Tamara Egger
Original Assignee
Antisense Pharma Gmbh
Karl-Hermann Schlingensiepen
Reimar Schlingensiepen
Piotr Jachimczak
Gerhard Stauder
Astrid Bischof
Michael Hafner
Tamara Egger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04004478A external-priority patent/EP1568383A3/en
Application filed by Antisense Pharma Gmbh, Karl-Hermann Schlingensiepen, Reimar Schlingensiepen, Piotr Jachimczak, Gerhard Stauder, Astrid Bischof, Michael Hafner, Tamara Egger filed Critical Antisense Pharma Gmbh
Priority to EP05715605A priority Critical patent/EP1722823A2/en
Priority to AU2005218759A priority patent/AU2005218759B2/en
Priority to MXPA06009794A priority patent/MXPA06009794A/en
Priority to US10/591,048 priority patent/US20070155685A1/en
Priority to JP2007500182A priority patent/JP5650367B2/en
Priority to CA002558667A priority patent/CA2558667A1/en
Publication of WO2005084712A2 publication Critical patent/WO2005084712A2/en
Priority to IL177480A priority patent/IL177480A0/en
Publication of WO2005084712A3 publication Critical patent/WO2005084712A3/en
Priority to AU2009222442A priority patent/AU2009222442B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Abstract

The present invention is related to pharmaceutical compositions for the inhibition of metastases and treatment of cancer such as bladder carcinoma, colon cancer, endometrial cancer, hepatocellular carcinoma, leukemia, lymphoma, melanoma, non-small cell lung cancer (NSCLC), ovarian cancer, pancreatic cancer, prostate cancer, soft tissue cancer, renal cancer, osteosarcoma, mesothelioma, myeloma multiple, bladder carcinoma and esophagcal cancer as well as the use of these pharmaceutical compositions for the treatment of said metastases and cancers. Another aspect of this invention are new antisense oligonucleotides inhibiting the formation of human interleukin 10 and their synthesis. A further aspect of this invention is the use IL-10 antisense oligonucleotides for the preparation of pharmaceutical compositions and for the treatment of cancer and metastases.
PCT/EP2005/002101 2004-02-27 2005-02-28 Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment WO2005084712A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP05715605A EP1722823A2 (en) 2004-02-27 2005-02-28 Pharmaceutical composition
AU2005218759A AU2005218759B2 (en) 2004-02-27 2005-02-28 Pharmaceutical composition
MXPA06009794A MXPA06009794A (en) 2004-02-27 2005-02-28 Pharmaceutical composition.
US10/591,048 US20070155685A1 (en) 2004-02-27 2005-02-28 Pharmaceutical composition
JP2007500182A JP5650367B2 (en) 2004-02-27 2005-02-28 Pharmaceutical composition
CA002558667A CA2558667A1 (en) 2004-02-27 2005-02-28 Antisense oligonucleotides for inhibiting the formation of metastases in cancer
IL177480A IL177480A0 (en) 2004-02-27 2006-08-14 Pharmaceutical composition
AU2009222442A AU2009222442B2 (en) 2004-02-27 2009-09-28 Pharmaceutical composition

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP04004478A EP1568383A3 (en) 2004-02-27 2004-02-27 Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment
EP04004478.6 2004-02-27
US55813504P 2004-04-01 2004-04-01
US60/558,135 2004-04-01

Publications (2)

Publication Number Publication Date
WO2005084712A2 WO2005084712A2 (en) 2005-09-15
WO2005084712A3 true WO2005084712A3 (en) 2006-12-28

Family

ID=34921301

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/002101 WO2005084712A2 (en) 2004-02-27 2005-02-28 Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment

Country Status (8)

Country Link
US (1) US20070155685A1 (en)
EP (1) EP1722823A2 (en)
JP (1) JP5650367B2 (en)
AU (2) AU2005218759B2 (en)
CA (1) CA2558667A1 (en)
IL (1) IL177480A0 (en)
MX (1) MXPA06009794A (en)
WO (1) WO2005084712A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102094572B1 (en) 2013-03-27 2020-03-30 이사르나 테라퓨틱스 게엠베하 Modified tgf-beta oligonucleotide for use in a method of preventing and/or treating an ophthalmic disease

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101543B2 (en) 2000-03-31 2006-09-05 Novarx Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells
CA2408011A1 (en) 2000-05-04 2001-11-08 Avi Biopharma, Inc. Splice-region antisense composition and method
DK1456380T3 (en) * 2001-11-02 2012-07-30 Giuliani Int Ltd SMAD7 inhibitors for the treatment of CNS diseases
ITRM20030149A1 (en) 2003-04-02 2004-10-03 Giuliani Spa ANTISENSE OLIGONUCLEOTIDES (ODN) FOR SMAD7 AND THEIR USE IN THE MEDICAL FIELD
ES2319332T3 (en) * 2005-05-05 2009-05-06 Antisense Pharma Gmbh THERAPEUTIC USE OF OLFONUCLEOTID ANTISENTIDO TGF-BETA 2 '.
JP5112322B2 (en) * 2005-10-24 2013-01-09 プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ Use of a TGF-β1 inhibitor peptide in the manufacture of an immune response modulator
GB0604966D0 (en) * 2006-03-11 2006-04-19 Renovo Ltd Medicaments and proteins
EP2468293B1 (en) 2006-09-28 2014-10-22 Merck Sharp & Dohme Corp. Use of pegylated il-10 to prevent metastasis of a cancer or tumor to the lung
AU2007347449A1 (en) 2007-02-16 2008-08-28 The Johns Hopkins University The microRNAome
US7989608B2 (en) * 2007-12-28 2011-08-02 Avi Biopharma Inc. Immunomodulatory agents and methods of use
US8822425B2 (en) * 2008-11-14 2014-09-02 Antisense Pharma Gmbh Dosage of oligonucleotides suitable for the treatment of tumors
ES2347627B1 (en) * 2009-03-06 2011-10-10 Isdin, S.A. PEPTIDE FOR PROFILACTIC OR THERAPEUTIC TREATMENT OF SKIN TUMORS IN INITIAL STAGES.
MX2012001244A (en) * 2009-07-30 2012-03-26 Antisense Pharma Gmbh Combination of a chemotherapeutic agent and an inhibitor of the tgf-beta system.
WO2011154542A1 (en) 2010-06-11 2011-12-15 Artisense Pharma Gmbh Method for selective oligonucleotide modification
EP2453017A1 (en) * 2010-11-12 2012-05-16 Antisense Pharma GmbH Oligonucleotides for use in prophylaxis and/or treatment of TGF-beta1 and TGF-beta2, TGF-beta2 and TGF-beta3, TGF-beta1 and TGF-beta3, or TGF-beta1, TGF-beta2, and TGF-beta3 mRNA overexpressing diseases
WO2012100931A1 (en) * 2011-01-24 2012-08-02 Eth Zurich New medical uses of tgf beta 1- specific irna
EP2683825B1 (en) 2011-03-11 2017-01-04 Sarissa Inc. Methods of treating cancer by inhibition of dna repair proteins
PL2978845T3 (en) 2013-03-27 2020-11-16 Isarna Therapeutics Gmbh Modified tgf-beta oligonucleotides
DK2978844T3 (en) * 2013-03-27 2020-11-16 Isarna Therapeutics Gmbh MODIFIED TGF-BETA2 OLIGONUCLEOTIDS
EP3041935A1 (en) * 2013-09-05 2016-07-13 Sage Therapeutics, Inc. Antisense-induced exon2 inclusion in acid alpha-glucosidase
US20170173180A1 (en) * 2014-03-27 2017-06-22 The Regents Of The University Of Michigan Cancer immunotherapy compositions and methods
US20180265874A1 (en) * 2014-10-10 2018-09-20 Global Biopharma, Inc. Methods for treating and/or preventing a tumor growth, invasion and/or metastasis
WO2016182513A1 (en) * 2015-05-13 2016-11-17 Singapore Health Services Pte Ltd Profiling of hepatocellular carcinoma and applications thereof
US10787664B2 (en) * 2015-05-26 2020-09-29 City Of Hope Compounds of chemically modified oligonucleotides and methods of use thereof
AU2016312510A1 (en) 2015-08-25 2018-03-08 Armo Biosciences, Inc. Methods of using Interleukin-10 for treating diseases and disorders
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
KR20180103816A (en) 2016-02-09 2018-09-19 오토텔릭 엘엘씨 Compositions and methods for treating pancreatic cancer
CA3125285A1 (en) * 2018-12-27 2020-07-02 Sirnaomics, Inc. Silencing tgf-beta 1 and cox2 using sirnas delivered in combination with immune checkpoint inhibitors to treat cancer
WO2023061888A1 (en) * 2021-10-13 2023-04-20 Universität Bern Nucleic acid agents for treatment of non-small-cell lung cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994025588A2 (en) * 1993-04-30 1994-11-10 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH ANTISENSE-OLIGONUCLEOTIDES FOR THE TREATMENT OF IMMUNOSUPPRESSIVE EFFECTS OF TRANSFORMING GROWTH FACTOR-β (TGF-β)
WO1999063975A2 (en) * 1998-06-10 1999-12-16 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH A method for stimulating the immune system

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) * 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4469863A (en) * 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US5023243A (en) * 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4452775A (en) * 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4999339A (en) * 1988-03-28 1991-03-12 Cetus Corporation Combination therapy of IL-2 and DTIC for the treatment of melanoma
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5550316A (en) * 1991-01-02 1996-08-27 Fox Chase Cancer Center Transgenic animal model system for human cutaneous melanoma
US5719262A (en) * 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5714331A (en) * 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5539082A (en) * 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5369527A (en) * 1992-12-03 1994-11-29 Mccracken; Robert Melanoma detection device
US5772995A (en) * 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
US6153388A (en) * 1994-10-27 2000-11-28 University Of South Florida Method of determining melanoma micrometastasis using tyrosinase
US5843974A (en) * 1995-06-06 1998-12-01 Eli Lilly And Company Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
EP0856579A1 (en) * 1997-01-31 1998-08-05 BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH An antisense oligonucleotide preparation method
AUPO864097A0 (en) * 1997-08-19 1997-09-11 Peplin Pty Ltd Anti-cancer compounds
EP1133988A1 (en) * 2000-03-11 2001-09-19 Biognostik Gesellschaft für biomolekulare Diagnostik mbH Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene
US7101543B2 (en) * 2000-03-31 2006-09-05 Novarx Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells
US20040006030A1 (en) * 2002-07-02 2004-01-08 Isis Pharmaceuticals Inc. Antisense modulation of TGF-beta 2 expression
US20070196269A1 (en) * 2003-12-19 2007-08-23 Karl-Hermann Schlingensiepen Pharmaceutical composition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994025588A2 (en) * 1993-04-30 1994-11-10 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH ANTISENSE-OLIGONUCLEOTIDES FOR THE TREATMENT OF IMMUNOSUPPRESSIVE EFFECTS OF TRANSFORMING GROWTH FACTOR-β (TGF-β)
WO1999063975A2 (en) * 1998-06-10 1999-12-16 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH A method for stimulating the immune system

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HUANG FEI ET AL: "Transforming growth factor beta-1 (TGF-beta-1) is an autocrine positive regulator of colon carcinoma U9 cells in vivo as shown by transfection of a TGF-beta-1 antisense expression plasmid", CELL GROWTH AND DIFFERENTIATION, vol. 6, no. 12, 1995, pages 1635 - 1642, XP009049279, ISSN: 1044-9523 *
JACHIMCZAK P ET AL: "TRANSFORMING GROWTH FACTOR-BETA-MEDIATED AUTOCRINE GROWTH REGULATION OF GLIOMAS AS DETECTED WITH PHOSPHOROTHIOATE ANTISENSE OLIGONUCLEOTIDES", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 65, no. 3, 26 January 1996 (1996-01-26), pages 332 - 337, XP000676566, ISSN: 0020-7136 *
PICON ANTONIO ET AL: "A subset of metastatic human colon cancers expresses elevated levels of transforming growth factor beta1", CANCER EPIDEMIOLOGY BIOMARKERS AND PREVENTION, vol. 7, no. 6, June 1998 (1998-06-01), pages 497 - 504, XP009049280, ISSN: 1055-9965 *
SPEARMAN M ET AL: "Antisense oligodeoxyribonucleotide inhibition of TGF-beta1 gene expression and alterations in the growth and malignant properties of mouse fibrosarcoma cells", GENE, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, NL, vol. 149, 1994, pages 25 - 29, XP002089439, ISSN: 0378-1119 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102094572B1 (en) 2013-03-27 2020-03-30 이사르나 테라퓨틱스 게엠베하 Modified tgf-beta oligonucleotide for use in a method of preventing and/or treating an ophthalmic disease

Also Published As

Publication number Publication date
WO2005084712A2 (en) 2005-09-15
AU2009222442A1 (en) 2009-10-15
CA2558667A1 (en) 2005-09-15
IL177480A0 (en) 2006-12-10
JP2007523943A (en) 2007-08-23
AU2005218759B2 (en) 2009-07-16
US20070155685A1 (en) 2007-07-05
JP5650367B2 (en) 2015-01-07
AU2009222442B2 (en) 2012-08-16
EP1722823A2 (en) 2006-11-22
MXPA06009794A (en) 2007-03-15
AU2005218759A1 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
WO2005084712A3 (en) Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment
EP2399611A3 (en) Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formaton of metasatases in cancer treatment
TW200628469A (en) Disubstituted pyrazolobenzodiazepines
IL184872A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
WO2002057261A3 (en) Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase
MY139355A (en) Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
WO2008081927A1 (en) Method for treating cancer using anticancer agent in combination
WO2006001956A3 (en) Compositions for inhibiting cell growth and inducing apoptosis in cancer cells and methods of use thereof
WO2005118824A8 (en) Methods and compositions for the inhibition of gene expression
SE0202539D0 (en) Compounds
NZ577916A (en) Cyclopamine analogs
WO2004005891A3 (en) Expression profile of lung cancer
WO2006034154A3 (en) Salts of 5-azacytidine
WO2003070283A3 (en) Agent for inhibiting development or progress of proliferative diseases and especially cancer diseases and pharmaceutical composition containing said agent
WO2008021038A3 (en) Pyridobenzazepine compounds and methods for inhibiting mitotic progression
MY148617A (en) 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
WO2003097835A3 (en) Pharmaceutical compositions for the treatment of cancer
WO2005000088A3 (en) Expression profile of pancreatic cancer
WO2006016912A3 (en) Synthesis of (-)-beta-elemene, (-)-beta-elemenal, (-)-beta-elemenol, (-)-beta-elemene fluoride and their analogues, intermediates and composition and uses thereof
WO2008144507A3 (en) Spirooxindole inhibitors of aurora kinase
WO2007035709A3 (en) Novel crystal forms of irinotecan hydrochloride
WO2003106384A3 (en) Novel boronic chalcone derivatives and uses thereof
MXPA05013210A (en) Cycloalkylsulfanyl substituted benzo[b]thiophenes as therapeutic agents.
TW200744603A (en) Novel anticancer concomitant drug
WO2004087673A3 (en) Migrastatin analogs and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005218759

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 177480

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2558667

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007500182

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/009794

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2005218759

Country of ref document: AU

Date of ref document: 20050228

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005218759

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005715605

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 5372/DELNP/2006

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2005715605

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10591048

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10591048

Country of ref document: US